Gamma Diagnostics
Gamma Diagnostics: A biotech firm innovating diagnostic solutions for infectious and chronic diseases.
Founded
2009Gamma Diagnostics: A biotech firm innovating diagnostic solutions for infectious and chronic diseases.
Gamma Diagnostics, founded with a mission to innovate diagnostic solutions, focuses on developing novel indicators for inflammatory responses in infectious and chronic diseases. The company offers products such as Gamma Prime Fibrinogen (GPF) and GammaCoeur™, which are designed to enhance the detection and management of clotting and inflammation, including conditions like COVID-19. Their market focus includes clinicians and healthcare providers who require advanced diagnostic tools to improve patient outcomes.
Notable figures affiliated with Gamma Diagnostics include leading scientists and industry experts in biotechnology and diagnostics. The company has garnered attention for its contributions to understanding and managing inflammatory responses, particularly during the COVID-19 pandemic. Key achievements include the development of proprietary diagnostic tests that have been published in reputable scientific journals. Overall, Gamma Diagnostics has made a significant impact by providing innovative solutions that address critical needs in healthcare diagnostics.
Companies similar to Gamma Diagnostics include Gamma Therapeutics, FYR Diagnostics, Epinex Diagnostics and Gema Diagnostics.
Gamma Diagnostics was founded in 2009.
Gamma Diagnostics' headquarters is located in Portland, OR, US.
Gamma Diagnostics' most recent funding round was for $100k (USD) in July 2021.
As of Jul 7, 2021, Gamma Diagnostics has disclosed funding of $100k (USD). Undisclosed round amounts are excluded.
Gamma Diagnostics has 4 employees as of Feb 5, 2024.
Gema Diagnostics
gemadx.com
